Meridian Bioscience (VIVO) 19.41 $VIVO
Bioline Launches New MyTaq(TM) Plant-PCR Kit
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaq(TM) Plant-PCR Kit, the latest in the line of kits from Bioline for direct PCR. The MyTaq(TM) Plant-PCR Kit is the first of many products Bioline is bringing to the agricultural market to advance plant genetic research. Bioline is also developing new technologies to support Agribio companies in their quest to improve agriculturally important plants.
VIVO: 19.41 (-0.17)
Meridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GlobeNewswire - Thu Apr 28, 6:45AM CDT
GENERAL HIGHLIGHTS
VIVO: 19.41 (-0.17)
Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae
Globe Newswire - Thu Apr 28, 1:00AM CDT
illumigene(R) Mycoplasma Direct provides fast and accurate results in less than 1 hour for immediate and targeted treatment
VIVO: 19.41 (-0.17)
Great Basin Announces Expansion of Executive Leadership
BusinessWire - Tue Apr 05, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today the expansion of the Company's leadership team with the appointment of Mike Blitz as vice president of U.S. sales, and the promotion of Sandra Nielsen to the position of senior vice president of sales and marketing. Previously, Ms. Nielsen served as the vice president of marketing and human resources and acting vice president of sales for Great Basin.
GBSN: 1.74 (-0.09), VIVO: 19.41 (-0.17), GBSNU: 16.22 (-0.28)
Upgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Tue Mar 29, 3:34AM CDT
Meridian Bioscience (NASDAQ:VIVO) was upgraded from Neutral to Buy at Hilliard Lyons today. The stock closed yesterday at $20.41 on volume of 288,000 shares, above average daily volume of 256,000. Meridian Bioscience, Inc. manufactures, markets, and distributes diagnostic test kits, purified reagents, and related products. The Company also offers bio- pharmaceutical enabling technologies. Meridian specializes in gastrointestinal and upper respiratory infections, serology, parasitology, and fungal disease diagnosis, as well as rare reagents and specialty biologicals.
VIVO: 19.41 (-0.17)
Meridian Bioscience Acquires Magellan Diagnostics, Inc.
GlobeNewswire - Thu Mar 24, 3:15PM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) announced today that it has completed the acquisition of Magellan Biosciences, Inc. and its wholly owned subsidiary Magellan Diagnostics, Inc. Headquartered in Billerica, Massachusetts (near Boston), Magellan pioneered the engineering, development and manufacturing of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults.
VIVO: 19.41 (-0.17)
Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Tue Mar 22, 3:45AM CDT
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Long-Term Buy to Neutral at Hilliard Lyons today. The stock closed yesterday at $20.00 on volume of 376,000 shares, above average daily volume of 272,000. Meridian Bioscience share prices have moved between a 52-week high of $21.40 and a 52-week low of $16.60 and closed yesterday at 20% above that low price at $20.00 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has advanced 0.4%.
VIVO: 19.41 (-0.17)
Meridian Bioscience Q1 Earnings in Line, Sales Miss Mark
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 10:30AM CST
Shares of diagnostic test-kit maker Meridian Bioscience Inc. (VIVO) rose 2% in the last three trading sessions following the company???s mixed first-quarter fiscal 2016 results.
VIVO: 19.41 (-0.17), STAA: 5.36 (-0.13), LMAT: 15.03 (-0.06), VASC: 39.58 (-0.56)
Meridian Bioscience Reports First Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GlobeNewswire - Wed Jan 27, 6:30AM CST
GENERAL HIGHLIGHTS
VIVO: 19.41 (-0.17)
Meridian Bioscience and Lean Continuous Improvements, LLC Collaborate to Apply Lean Principles to Recent Launch of illumigene(R) Malaria
GlobeNewswire - Tue Jan 26, 11:03AM CST
Meridian Bioscience, Inc. announced today that the recent product transfer and launch of its innovative molecular test illumigene Malaria was accomplished on an accelerated schedule via a collaboration with Lean Continuous Improvements, LLC (LCI). The development and transfer of medical devices is a complicated and highly regulated process. Meridian recognized the need to streamline the tasks and activities required to move a new test from the product development phase through to final regulatory approval, and ultimately to our lab customers. Lean Continuous Improvements is a Cincinnati-based consulting firm that is expert in applying lean principles, in conjunction with project management, that minimize wasted time, that help facilitate conflict resolution and that increase the team's energy while maximizing product quality.
VIVO: 19.41 (-0.17)
New Malaria Test, illumigene(R) Malaria, Sets a New Gold Standard for Diagnosis
GlobeNewswire - Tue Jan 26, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for illumigene Malaria, a novel, highly accurate test developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal. The test is up to 80,000 times more sensitive at detecting the malaria parasite than conventional tests, potentially revolutionizing malaria diagnosis and establishing a new gold standard. Using innovative molecular LAMP technology, illumigene results are available in under one hour, and the test is easy to use as it does not rely on high level technical expertise. This is a major step forward for people with malaria as faster, more accurate diagnoses should lead to prompt treatment and better outcomes. illumigene Malaria will be distributed in the European, Middle Eastern and African regions by Meridian Bioscience Europe and in additional international markets by the Company's global distribution network.
VIVO: 19.41 (-0.17)
High-Growth Diagnostic Testing Markets Report - 2016 Edition
M2 - Fri Jan 22, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzwf2g/highgrowth) has announced the addition of the "High-Growth Diagnostic Testing Markets" report to their offering. There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned - A Menarini Diagnostics - Abaxis, Inc - Abbott Laboratories - Accurex Biomedical Pvt Ltd - Adeza Biomedical Corporation (Hologic) - Agilent Technologies, Inc - American Bio Medica Corporation - Ani Biotech Oy Ltd - Applied Spectral Imaging - Avitar, Inc - Axis-Shield Plc - Bayer Corporation - Beckman Coulter (now part of Danaher) - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc - Biomerica, Inc - Enterix, Inc (Subsidiary of Quest Diagnostics) - Genetix (Molecular Devices) - Genzyme Diagnostics - Hologic Gen Probe - LifeScan - Matritech - Medix Biochemica - Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc) - Meridian Bioscience - Myriad Genetics, Inc - NOVA Biomedical - OraSure - Roche Diagnostics - Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech) - Shionogi & Co, Ltd - Siemens Healthcare Diagnostics - Spectral Diagnostics, Inc - Trinity Biotech Plc - V?samed, Inc For more information visit http://www.researchandmarkets.com/research/gzwf2g/highgrowth
ABT: 38.40 (-0.47), MYGN: 30.95 (-3.07), VIVO: 19.41 (-0.17), A: 45.36 (-0.73), DHR: 99.31 (-1.08), ABAX: 45.53 (-1.36), DGX: 77.45 (-1.30), TRIB: 10.93 (-0.27), HOLX: 34.14 (-0.81)
Global Point of Care (POC) Pregnancy and Fertility Testing Market Report 2015
M2 - Tue Jan 19, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/d22vw2/poc_pregnancy_and) has announced the addition of the "POC Pregnancy and Fertility Testing Market" report to their offering. The female reproductive system is complex both in structure and in function. From birth to senescence, the organs of the female reproductive system function in concert with each other, with the brain, and with other endocrine organs. This integrated functioning constitutes some of the most intricate and elegant processes of the human body. Because the functioning of the female reproductive system has an enormous impact on the life of the individual women, increasing importance is placed on the active involvement of women in understanding their own health care needs such as determination of pregnancy and fertility. Point of care (POC) testing, diagnostic tests performed at or near the site where a patient is located, may be performed by laboratory personnel but are often performed by non-laboratory personnel, including patients themselves (self-testing). The menu for POC testing includes pregnancy and fertility testing. Point of Care (POC) Pregnancy and Fertility Testing Market examines the testing market for these segments, including: - 2014 Pregnancy and Fertility CLIA Waivers - Global POC Pregnancy and Fertility Testing Market Analysis, 2012-2019 - POC Pregnancy and Fertility Self-Testing Market Analysis, 2014 and 2019 - POC Pregnancy and Fertility Professional Testing Market Analysis, 2014 and 2019 - Global POC Pregnancy and Fertility Testing Market Revenues and Market Share of Leading Suppliers, 2014 The professional sector is made up of tests used in hospitals, physician offices and clinics. The over-the-counter (OTC) sector for pregnancy and ovulation (LH) includes tests available in pharmacies and other retail establishments. Both market segments are expected to grow over the report's forecast period. Many companies are involved in the development and/or marketing of POC pregnancy and fertility testing products. Among the top and/or innovative competitors discussed within the Corporate Profiles are firms that maintain leading positions in the market such as: - Alere - Church & Dwight - Insight Pharmaceuticals - Meridian - Quidel Key Topics Covered: ONE: EXECUTIVE SUMMARY - Overview of POC Testing - Pregnancy and Fertility - Size of the Market - POC Professional Testing - POC Pregnancy and Fertility Self-Testing - Growth of the Market - Leading Competitors TWO: POC PREGNANCY AND FERTILITY TESTING - Products - Market Size and Growth - POC Pregnancy and Fertility Self-Testing - POC Pregnancy and Fertility Professional Testing - Competitive Analysis - Product Innovation THREE: CORPORATE PROFILES - Alere Inc - Ani Biotech Oy - Beckman Coulter, Inc - bioMerieux SA - Cen-Med Enterprises, Inc. - Church & Dwight Co., Inc - EKF Diagnostics GmbH - EKLA Corporation - Insight Pharmaceuticals LLC - Meridian BioScience, Inc - Opko Health, Inc - Polymed Therapeutics Inc. - Polymedco, Inc - Quidel Corporation - Radiometer Medical ApS - Ramco Laboratories, Inc. - Roche Diagnostics Corporation - Siemens Healthcare - Stanbio Laboratory - Trinity Biotech Plc For more information visit http://www.researchandmarkets.com/research/d2...gnancy_and
CHD: 99.88 (+0.05), VIVO: 19.41 (-0.17), OPK: 9.30 (-0.31), TRIB: 10.93 (-0.27), ALR: 42.78 (+0.10)
Meridian Bioscience at 52-Week High on Product Launches
Zacks Equity Research - Zacks Investment Research - Wed Dec 30, 12:10PM CST
Shares of Meridian Bioscience Inc. (VIVO) rallied to a new 52-week high of $20.92 on Dec 29 and closed a tad bit lower at $20.76.
ICUI: 107.33 (-0.80), INSY: 13.99 (-2.04), NXTM: 20.63 (-0.36), VIVO: 19.41 (-0.17)
Meridian Bioscience Up 12.0% Since SmarTrend Uptrend Call (VIVO)
Comtex SmarTrend(R) - Thu Dec 24, 5:20PM CST
SmarTrend identified an Uptrend for Meridian Bioscience (NASDAQ:VIVO) on October 23rd, 2015 at $18.32. In approximately 2 months, Meridian Bioscience has returned 11.98% as of today's recent price of $20.51.
VIVO: 19.41 (-0.17)
10.4% Return Seen to Date on SmarTrend Meridian Bioscience Call (VIVO)
Comtex SmarTrend(R) - Wed Dec 16, 6:31PM CST
SmarTrend identified an Uptrend for Meridian Bioscience (NASDAQ:VIVO) on October 23rd, 2015 at $18.32. In approximately 2 months, Meridian Bioscience has returned 10.40% as of today's recent price of $20.22.
VIVO: 19.41 (-0.17)
GI Stool Testing (FOBT & Clinical Microbiology Stool Test) Market 2015-2019 with Clinical Genomics, Diasorin, Meridian Bioscience & Quidel Dominating
PR Newswire Europe - Mon Dec 14, 5:08AM CST
DUBLIN, December 14, 2015 /PRNewswire/ --
VIVO: 19.41 (-0.17)
Bioline Launches New MyTaq(TM) Plant-PCR Kit
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaq(TM) Plant-PCR Kit, the latest in the line of kits from Bioline for direct PCR. The MyTaq(TM) Plant-PCR Kit is the first of many products Bioline is bringing to the agricultural market to advance plant genetic research. Bioline is also developing new technologies to support Agribio companies in their quest to improve agriculturally important plants.
VIVO: 19.41 (-0.17)
Meridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GlobeNewswire - Thu Apr 28, 6:45AM CDT
GENERAL HIGHLIGHTS
VIVO: 19.41 (-0.17)
Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae
Globe Newswire - Thu Apr 28, 1:00AM CDT
illumigene(R) Mycoplasma Direct provides fast and accurate results in less than 1 hour for immediate and targeted treatment
VIVO: 19.41 (-0.17)
Great Basin Announces Expansion of Executive Leadership
BusinessWire - Tue Apr 05, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today the expansion of the Company's leadership team with the appointment of Mike Blitz as vice president of U.S. sales, and the promotion of Sandra Nielsen to the position of senior vice president of sales and marketing. Previously, Ms. Nielsen served as the vice president of marketing and human resources and acting vice president of sales for Great Basin.
GBSN: 1.74 (-0.09), VIVO: 19.41 (-0.17), GBSNU: 16.22 (-0.28)
Upgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Tue Mar 29, 3:34AM CDT
Meridian Bioscience (NASDAQ:VIVO) was upgraded from Neutral to Buy at Hilliard Lyons today. The stock closed yesterday at $20.41 on volume of 288,000 shares, above average daily volume of 256,000. Meridian Bioscience, Inc. manufactures, markets, and distributes diagnostic test kits, purified reagents, and related products. The Company also offers bio- pharmaceutical enabling technologies. Meridian specializes in gastrointestinal and upper respiratory infections, serology, parasitology, and fungal disease diagnosis, as well as rare reagents and specialty biologicals.
VIVO: 19.41 (-0.17)
Meridian Bioscience Acquires Magellan Diagnostics, Inc.
GlobeNewswire - Thu Mar 24, 3:15PM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) announced today that it has completed the acquisition of Magellan Biosciences, Inc. and its wholly owned subsidiary Magellan Diagnostics, Inc. Headquartered in Billerica, Massachusetts (near Boston), Magellan pioneered the engineering, development and manufacturing of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults.
VIVO: 19.41 (-0.17)
Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Tue Mar 22, 3:45AM CDT
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Long-Term Buy to Neutral at Hilliard Lyons today. The stock closed yesterday at $20.00 on volume of 376,000 shares, above average daily volume of 272,000. Meridian Bioscience share prices have moved between a 52-week high of $21.40 and a 52-week low of $16.60 and closed yesterday at 20% above that low price at $20.00 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has advanced 0.4%.
VIVO: 19.41 (-0.17)
Meridian Bioscience Q1 Earnings in Line, Sales Miss Mark
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 10:30AM CST
Shares of diagnostic test-kit maker Meridian Bioscience Inc. (VIVO) rose 2% in the last three trading sessions following the company???s mixed first-quarter fiscal 2016 results.
VIVO: 19.41 (-0.17), STAA: 5.36 (-0.13), LMAT: 15.03 (-0.06), VASC: 39.58 (-0.56)
Meridian Bioscience Reports First Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GlobeNewswire - Wed Jan 27, 6:30AM CST
GENERAL HIGHLIGHTS
VIVO: 19.41 (-0.17)
Meridian Bioscience and Lean Continuous Improvements, LLC Collaborate to Apply Lean Principles to Recent Launch of illumigene(R) Malaria
GlobeNewswire - Tue Jan 26, 11:03AM CST
Meridian Bioscience, Inc. announced today that the recent product transfer and launch of its innovative molecular test illumigene Malaria was accomplished on an accelerated schedule via a collaboration with Lean Continuous Improvements, LLC (LCI). The development and transfer of medical devices is a complicated and highly regulated process. Meridian recognized the need to streamline the tasks and activities required to move a new test from the product development phase through to final regulatory approval, and ultimately to our lab customers. Lean Continuous Improvements is a Cincinnati-based consulting firm that is expert in applying lean principles, in conjunction with project management, that minimize wasted time, that help facilitate conflict resolution and that increase the team's energy while maximizing product quality.
VIVO: 19.41 (-0.17)
New Malaria Test, illumigene(R) Malaria, Sets a New Gold Standard for Diagnosis
GlobeNewswire - Tue Jan 26, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for illumigene Malaria, a novel, highly accurate test developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal. The test is up to 80,000 times more sensitive at detecting the malaria parasite than conventional tests, potentially revolutionizing malaria diagnosis and establishing a new gold standard. Using innovative molecular LAMP technology, illumigene results are available in under one hour, and the test is easy to use as it does not rely on high level technical expertise. This is a major step forward for people with malaria as faster, more accurate diagnoses should lead to prompt treatment and better outcomes. illumigene Malaria will be distributed in the European, Middle Eastern and African regions by Meridian Bioscience Europe and in additional international markets by the Company's global distribution network.
VIVO: 19.41 (-0.17)
High-Growth Diagnostic Testing Markets Report - 2016 Edition
M2 - Fri Jan 22, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzwf2g/highgrowth) has announced the addition of the "High-Growth Diagnostic Testing Markets" report to their offering. There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned - A Menarini Diagnostics - Abaxis, Inc - Abbott Laboratories - Accurex Biomedical Pvt Ltd - Adeza Biomedical Corporation (Hologic) - Agilent Technologies, Inc - American Bio Medica Corporation - Ani Biotech Oy Ltd - Applied Spectral Imaging - Avitar, Inc - Axis-Shield Plc - Bayer Corporation - Beckman Coulter (now part of Danaher) - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc - Biomerica, Inc - Enterix, Inc (Subsidiary of Quest Diagnostics) - Genetix (Molecular Devices) - Genzyme Diagnostics - Hologic Gen Probe - LifeScan - Matritech - Medix Biochemica - Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc) - Meridian Bioscience - Myriad Genetics, Inc - NOVA Biomedical - OraSure - Roche Diagnostics - Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech) - Shionogi & Co, Ltd - Siemens Healthcare Diagnostics - Spectral Diagnostics, Inc - Trinity Biotech Plc - V?samed, Inc For more information visit http://www.researchandmarkets.com/research/gzwf2g/highgrowth
ABT: 38.40 (-0.47), MYGN: 30.95 (-3.07), VIVO: 19.41 (-0.17), A: 45.36 (-0.73), DHR: 99.31 (-1.08), ABAX: 45.53 (-1.36), DGX: 77.45 (-1.30), TRIB: 10.93 (-0.27), HOLX: 34.14 (-0.81)
Global Point of Care (POC) Pregnancy and Fertility Testing Market Report 2015
M2 - Tue Jan 19, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/d22vw2/poc_pregnancy_and) has announced the addition of the "POC Pregnancy and Fertility Testing Market" report to their offering. The female reproductive system is complex both in structure and in function. From birth to senescence, the organs of the female reproductive system function in concert with each other, with the brain, and with other endocrine organs. This integrated functioning constitutes some of the most intricate and elegant processes of the human body. Because the functioning of the female reproductive system has an enormous impact on the life of the individual women, increasing importance is placed on the active involvement of women in understanding their own health care needs such as determination of pregnancy and fertility. Point of care (POC) testing, diagnostic tests performed at or near the site where a patient is located, may be performed by laboratory personnel but are often performed by non-laboratory personnel, including patients themselves (self-testing). The menu for POC testing includes pregnancy and fertility testing. Point of Care (POC) Pregnancy and Fertility Testing Market examines the testing market for these segments, including: - 2014 Pregnancy and Fertility CLIA Waivers - Global POC Pregnancy and Fertility Testing Market Analysis, 2012-2019 - POC Pregnancy and Fertility Self-Testing Market Analysis, 2014 and 2019 - POC Pregnancy and Fertility Professional Testing Market Analysis, 2014 and 2019 - Global POC Pregnancy and Fertility Testing Market Revenues and Market Share of Leading Suppliers, 2014 The professional sector is made up of tests used in hospitals, physician offices and clinics. The over-the-counter (OTC) sector for pregnancy and ovulation (LH) includes tests available in pharmacies and other retail establishments. Both market segments are expected to grow over the report's forecast period. Many companies are involved in the development and/or marketing of POC pregnancy and fertility testing products. Among the top and/or innovative competitors discussed within the Corporate Profiles are firms that maintain leading positions in the market such as: - Alere - Church & Dwight - Insight Pharmaceuticals - Meridian - Quidel Key Topics Covered: ONE: EXECUTIVE SUMMARY - Overview of POC Testing - Pregnancy and Fertility - Size of the Market - POC Professional Testing - POC Pregnancy and Fertility Self-Testing - Growth of the Market - Leading Competitors TWO: POC PREGNANCY AND FERTILITY TESTING - Products - Market Size and Growth - POC Pregnancy and Fertility Self-Testing - POC Pregnancy and Fertility Professional Testing - Competitive Analysis - Product Innovation THREE: CORPORATE PROFILES - Alere Inc - Ani Biotech Oy - Beckman Coulter, Inc - bioMerieux SA - Cen-Med Enterprises, Inc. - Church & Dwight Co., Inc - EKF Diagnostics GmbH - EKLA Corporation - Insight Pharmaceuticals LLC - Meridian BioScience, Inc - Opko Health, Inc - Polymed Therapeutics Inc. - Polymedco, Inc - Quidel Corporation - Radiometer Medical ApS - Ramco Laboratories, Inc. - Roche Diagnostics Corporation - Siemens Healthcare - Stanbio Laboratory - Trinity Biotech Plc For more information visit http://www.researchandmarkets.com/research/d2...gnancy_and
CHD: 99.88 (+0.05), VIVO: 19.41 (-0.17), OPK: 9.30 (-0.31), TRIB: 10.93 (-0.27), ALR: 42.78 (+0.10)
Meridian Bioscience at 52-Week High on Product Launches
Zacks Equity Research - Zacks Investment Research - Wed Dec 30, 12:10PM CST
Shares of Meridian Bioscience Inc. (VIVO) rallied to a new 52-week high of $20.92 on Dec 29 and closed a tad bit lower at $20.76.
ICUI: 107.33 (-0.80), INSY: 13.99 (-2.04), NXTM: 20.63 (-0.36), VIVO: 19.41 (-0.17)
Meridian Bioscience Up 12.0% Since SmarTrend Uptrend Call (VIVO)
Comtex SmarTrend(R) - Thu Dec 24, 5:20PM CST
SmarTrend identified an Uptrend for Meridian Bioscience (NASDAQ:VIVO) on October 23rd, 2015 at $18.32. In approximately 2 months, Meridian Bioscience has returned 11.98% as of today's recent price of $20.51.
VIVO: 19.41 (-0.17)
10.4% Return Seen to Date on SmarTrend Meridian Bioscience Call (VIVO)
Comtex SmarTrend(R) - Wed Dec 16, 6:31PM CST
SmarTrend identified an Uptrend for Meridian Bioscience (NASDAQ:VIVO) on October 23rd, 2015 at $18.32. In approximately 2 months, Meridian Bioscience has returned 10.40% as of today's recent price of $20.22.
VIVO: 19.41 (-0.17)
GI Stool Testing (FOBT & Clinical Microbiology Stool Test) Market 2015-2019 with Clinical Genomics, Diasorin, Meridian Bioscience & Quidel Dominating
PR Newswire Europe - Mon Dec 14, 5:08AM CST
DUBLIN, December 14, 2015 /PRNewswire/ --
VIVO: 19.41 (-0.17)
